CO2019012356A2 - Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso - Google Patents

Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso

Info

Publication number
CO2019012356A2
CO2019012356A2 CONC2019/0012356A CO2019012356A CO2019012356A2 CO 2019012356 A2 CO2019012356 A2 CO 2019012356A2 CO 2019012356 A CO2019012356 A CO 2019012356A CO 2019012356 A2 CO2019012356 A2 CO 2019012356A2
Authority
CO
Colombia
Prior art keywords
antibodies
methods
programmed death
death receptor
combination
Prior art date
Application number
CONC2019/0012356A
Other languages
English (en)
Spanish (es)
Inventor
Arnab De
Chakravarthy Nachu Narasimhan
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64016405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019012356(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CO2019012356A2 publication Critical patent/CO2019012356A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CONC2019/0012356A 2017-05-02 2019-11-01 Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso CO2019012356A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762500278P 2017-05-02 2017-05-02
PCT/US2018/030516 WO2018204405A1 (en) 2017-05-02 2018-05-01 Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2019012356A2 true CO2019012356A2 (es) 2020-01-17

Family

ID=64016405

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0012356A CO2019012356A2 (es) 2017-05-02 2019-11-01 Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso

Country Status (15)

Country Link
US (2) US20200354453A1 (enExample)
EP (1) EP3618855A4 (enExample)
JP (2) JP7402693B2 (enExample)
KR (1) KR102770786B1 (enExample)
CN (1) CN110603052A (enExample)
AU (1) AU2018261080A1 (enExample)
BR (1) BR112019022698A2 (enExample)
CA (1) CA3061050A1 (enExample)
CL (1) CL2019003145A1 (enExample)
CO (1) CO2019012356A2 (enExample)
IL (1) IL270175B2 (enExample)
MA (1) MA50661A (enExample)
MX (1) MX2019013033A (enExample)
SG (2) SG11201909941QA (enExample)
WO (1) WO2018204405A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
CN115925931A (zh) * 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
EP3876978A4 (en) * 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
AU2019395841B2 (en) * 2018-12-14 2025-02-27 Morphosys Ag Antibody formulations
CN113840840A (zh) * 2019-06-13 2021-12-24 株式会社绿十字 Tigit抗体及其用途
WO2021013689A1 (en) * 2019-07-19 2021-01-28 Ichnos Sciences SA Lyophilized antibody formulation
CN112741804A (zh) * 2019-10-31 2021-05-04 上海君实生物医药科技股份有限公司 含有抗pd-l1抗体的稳定制剂
US20230080706A1 (en) * 2020-01-21 2023-03-16 Innovent Biologics (Suzhou) Co., Ltd. Recombinant fully human anti-tigit monoclonal antibody formulation, method for preparing same and use thereof
KR20220131923A (ko) 2020-01-24 2022-09-29 리제너론 파마슈티칼스 인코포레이티드 안정한 항체 제형
CN114507284B (zh) * 2020-05-09 2023-05-26 华博生物医药技术（上海）有限公司 抗tigit的抗体、其制备方法和应用
AU2021284273A1 (en) * 2020-06-02 2022-12-15 Arcus Biosciences, Inc. Antibodies to TIGIT
WO2021257124A1 (en) 2020-06-18 2021-12-23 Genentech, Inc. Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
CN111718415B (zh) * 2020-07-03 2021-02-23 上海洛启生物医药技术有限公司 一种抗tigit纳米抗体及其应用
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US20220233693A1 (en) * 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
CN114762678B (zh) * 2021-01-14 2024-03-15 上海君实生物医药科技股份有限公司 抗tigit抗体药物组合物及其用途
AR124712A1 (es) 2021-01-29 2023-04-26 Merck Sharp & Dohme Composiciones de anticuerpos del receptor de muerte programada 1 (pd-1) y métodos para obtener las composiciones de los mismos
AR125753A1 (es) 2021-05-04 2023-08-09 Agenus Inc Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
EP4375300A4 (en) * 2021-07-23 2025-08-27 Akeso Biopharma Inc PHARMACEUTICAL COMPOSITION AND ITS USE
EP4377350A2 (en) 2021-07-28 2024-06-05 Genentech, Inc. Methods and compositions for treating cancer
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
CN114106182B (zh) * 2022-01-26 2022-05-17 中山康方生物医药有限公司 抗tigit的抗体及其用途
EP4507726A1 (en) * 2022-04-14 2025-02-19 BeiGene Switzerland GmbH Stable high concentration arginine formulations containing pd-1 antibody and methods of use thereof
KR20250022049A (ko) 2022-06-07 2025-02-14 제넨테크, 인크. 항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
US20250362305A1 (en) * 2022-08-04 2025-11-27 Merck Sharp & Dohme Llc Methods for determining one or more critical quality attributes of co-formulated antibodies
WO2024140651A1 (zh) * 2022-12-27 2024-07-04 上海复宏汉霖生物技术股份有限公司 包含抗tigit抗体的药物制剂
WO2025166550A1 (zh) * 2024-02-06 2025-08-14 香港北恒生物科技有限公司 工程化细胞及其用途
CN121003695A (zh) * 2024-05-24 2025-11-25 百奥泰生物制药股份有限公司 抗tigit抗体和抗pd-1抗体联合治疗肿瘤
WO2025248110A1 (en) 2024-05-31 2025-12-04 Replimune Limited An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831129A (en) * 2006-10-06 2008-08-01 Amgen Inc Stable formulations
WO2011008770A2 (en) * 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
EP2399604A1 (en) * 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
AU2012236479B2 (en) * 2011-03-31 2016-10-20 Merck Sharp & Dohme Llc Stable formulations of antibodies to human programmed death receptor PD-1 and related treatments
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
SG11201600310QA (en) * 2013-07-16 2016-02-26 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
JO3664B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme أجسام مضادة لـ tigit
CN110256558B (zh) * 2014-12-23 2023-07-04 百时美施贵宝公司 针对tigit的抗体
US20180251548A1 (en) * 2015-09-14 2018-09-06 Compass Therapeutics Llc Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
EP3394099A4 (en) * 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulations of Manipulated Anti- IL-10 Antibodies
AU2017257505B2 (en) * 2016-04-25 2020-05-14 Medimmune, Llc Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies
MX2019013034A (es) * 2017-05-02 2020-02-05 Merck Sharp & Dohme Formulaciones estables de anticuerpos anti-ctla4 solos y en combinacion con anticuerpos contra el receptor de muerte programasa 1 (pd-1) y metodos para su uso.

Also Published As

Publication number Publication date
SG11201909941QA (en) 2019-11-28
MX2019013033A (es) 2020-02-05
AU2018261080A1 (en) 2019-11-07
IL270175B1 (en) 2023-05-01
SG10202111905PA (en) 2021-12-30
CN110603052A (zh) 2019-12-20
US20200354453A1 (en) 2020-11-12
KR102770786B1 (ko) 2025-02-20
WO2018204405A1 (en) 2018-11-08
JP7402693B2 (ja) 2023-12-21
KR20190142394A (ko) 2019-12-26
EP3618855A1 (en) 2020-03-11
CA3061050A1 (en) 2018-11-08
EP3618855A4 (en) 2021-02-17
RU2019138519A (ru) 2021-06-02
MA50661A (fr) 2020-08-05
IL270175B2 (en) 2023-09-01
BR112019022698A2 (pt) 2020-05-19
US20240182573A1 (en) 2024-06-06
IL270175A (enExample) 2019-12-31
JP2024016177A (ja) 2024-02-06
JP2020518600A (ja) 2020-06-25
CL2019003145A1 (es) 2020-07-10
RU2019138519A3 (enExample) 2021-08-30

Similar Documents

Publication Publication Date Title
CO2019012356A2 (es) Formulaciones estables de anticuerpos anti-tigit solos y en combinación con anticuerpos receptores de muerte programada 1 (pd-1) y métodos para su uso
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2023001092A1 (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
CL2020000938A1 (es) Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744)
CL2017003195A1 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso.
MX393951B (es) Anticuerpos antisortilina y métodos para su uso.
CL2021001686A1 (es) Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
IL280467A (en) Antibody constructs for cldn18.2 and cd3
ECSP19078414A (es) Anticuerpos anti-cd33 y métodos para utilizarlos
MX2019011927A (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
BR112018012113A2 (pt) anticorpos monoclonais de ctla4 anti-humana quiméricos e humanizados e usos dos mesmo
MX390920B (es) Moléculas de unión a lag-3 y métodos de uso de las mismas.
BR112018012801A2 (pt) combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 para tratar o câncer
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
CL2021000736A1 (es) Receptor de antígeno quimérico.
MX2020013905A (es) Metodos para el tratamiento del cancer con anticuerpos anti-cd3xmuc16 y anticuerpos anti-pd-1 biespecificos.
MX386942B (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
PE20210186A1 (es) Anticuerpos anti-sortilina y metodos para su uso
BR112017019617A2 (pt) Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
MX2021002299A (es) Anticuerpos de anti-cd33 y metodos para usarlos.
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
BR112021020532A2 (pt) Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека